目的 運用CiteSpace軟件對蒼術Atractlodis Rhizoma的研究熱點及發(fā)展趨勢進行可視化分析，為其深入研究提供參考。方法 分別檢索中國學術期刊全文數(shù)據(jù)庫（CNKI）、Web of Science數(shù)據(jù)庫中收錄的，2003年1月1日—2024年12月31日蒼術相關研究文獻，運用CiteSpace 6.3.R1軟件對發(fā)文作者、研究機構、關鍵詞共現(xiàn)、關鍵詞突現(xiàn)等內容進行可視化圖譜分析，并對蒼術研究現(xiàn)狀及發(fā)展趨勢進行分析歸納。結果 篩選后共納入861篇中文文獻，339篇英文文獻，中、英文文獻年發(fā)文量均呈震蕩波動上升趨勢；《中成藥》《Journal of Ethnopharmacology》分別是發(fā)表中文和英文文獻最多的期刊，劉艷菊、Dai Chuanchao分別是發(fā)表中文和英文文獻最多的作者，發(fā)文量較高的研究機構為中國中醫(yī)科學院（China Academy of Chinese Medical Sciences）、湖北中醫(yī)藥大學、南京中醫(yī)藥大學、南京師范大學（Nanjing Normal University），機構間形成一定合作規(guī)模；關鍵詞分析顯示，頻次較高且中介中心性較強的關鍵詞有“蒼術”“蒼術素”“茅蒼術”“ expression”“rhizomes”“apoptosis”等，中文關鍵詞研究熱點聚焦于傳統(tǒng)中藥的品種鑒別、道地性特征及藥效物質基礎；英文關鍵詞研究熱點則集中于分子機制探索、細胞生物學效應及活性成分的藥理作用路徑。關鍵詞共生成19個聚類歸納出以下5個研究熱點：蒼術資源與種植、質量評價與鑒別、炮制相關與機制研究、藥理作用與機制研究、臨床應用及配伍療效。結論 現(xiàn)階段已對蒼術功效、藥理作用、炮制機制和栽培種植等方面進行深入研究，但仍在持續(xù)發(fā)展階段，特別是在蒼術種植栽培、炮制降燥增效機制、臨床療效評價等方面，研究尚存在不足，未來仍有較大的完善空間與深度挖掘價值。

Objective To research hotspots and development trends of Cangzhu (Atractylodis Rhizoma), so as to provide references for in-depth investigations into this medicinal herb. Methods Literature related to Atractylodis Rhizoma published between January 1, 2003, and December 31, 2024, was retrieved from the China National Knowledge Infrastructure (CNKI) and Web of Science databases. Using CiteSpace 6.3.R1 software, the data were systematically organized and visually analyzed to generate co-authorship networks, institutional collaboration maps, keyword co-occurrence clusters, and bursty keyword detection. This study synthesizes the current research landscape and future trends in Atractylodis Rhizoma research, providing a comprehensive reference for in-depth investigations. Results A total of 861 Chinese literatures and 339 English literatures were included through screening. The annual number of published papers shows an oscillating upward trend. Chinese Journal of Traditional Patent Medicine and Journal of Ethnopharmacology were the journals with the most publications in Chinese and English, respectively. Liu Yanju and Dai Chuanchao were the authors with the most publications in Chinese and English, respectively. The research institutions with high publication volumes included China Academy of Chinese Medical Sciences, Hubei University of Chinese Medicine, Nanjing University of Chinese Medicine, and Nanjing Normal University, forming a certain scale of cooperation among institutions. Keyword analysis showed that keywords with high frequency and strong betweenness centrality included "Cangzhu", "Atractylodin", "Atractylodes lancea", "expression", "rhizome", "apoptosis", etc. The research hotspots of Chinese keywords focused on the variety identification, genuine characteristics, and pharmacodynamic material basis of traditional Chinese medicine, while the research hotspots of English keywords concentrated on the exploration of molecular mechanisms, cell biological effects, and pharmacological action pathways of active ingredients. A total of 19 clusters were generated from the keywords, which were summarized into the following 5 research hotspots: Atractylodis Rhizoma resources and cultivation, quality evaluation and identification, processing-related and mechanism research, pharmacological effects and mechanism research, clinical application and compatibility efficacy. Conclusion At present, in-depth research has been carried out on the efficacy, pharmacological effects, processing mechanisms, and cultivation of Atractylodis Rhizoma However, it is still in a stage of continuous development. Especially in aspects such as the cultivation of Atractylodis Rhizoma, the mechanism of reducing dryness and enhancing efficacy in processing, and the evaluation of clinical efficacy, There are still deficiencies in the research, and there is still considerable room for improvement and potential for in-depth exploration in the future.

R282.71

國家自然科學基金資助項目（82360771）；國家重點研發(fā)計劃“中醫(yī)藥現(xiàn)代化研究”重點專項（2023YFC3504205）；特色炮制技術規(guī)律發(fā)掘——麩制項目（GZY-KJS-2022-051）；中藥炮制技術傳承創(chuàng)新團隊項目（CXTD22003）；中藥炮制（炆法）等關鍵技術重點研究室項目（贛中醫(yī)藥科教字〔2022〕8號）；江西省“雙千人才”計劃項目［贛才辦字（2019）9號］；江西省中醫(yī)藥產業(yè)科技創(chuàng)新聯(lián)合體產業(yè)鏈協(xié)同攻關項目（20224BBG72001）；江西省自然科學基金項目（20224ACB206048）；中藥炮制傳承創(chuàng)新與轉化江西省重點實驗室項目（2024SSY07091）；建昌幫特色飲片炮制工藝及質量標準規(guī)范化研究項目（JCB-202302-033）；江西省標準創(chuàng)新基地（醫(yī)藥）